source
- Eyepoint's wet AMD therapy misses primary goal in Phase 3, stock tumblesEyepoint reported that its experimental drug Duravyu did not keep vision in patients with wet age-related macular degeneration when given less frequently than the standard of care, causing the Phas…
- Sanofi to cut 229 Massachusetts jobs a year after $9.1 billion Blueprint Medicines acquisitionSanofi announced it will lay off 229 employees in Massachusetts, according to a filing with the state's Executive Office of Labor and Workforce Development. The workers are from Blueprint Medicine…